Since 1 febuxostat can reduce uric acid, why can't it be used for the treatment of asymptomatic hyperuricemia?
In the drug instructions of febuxostat, only gout patients are recommended for long-term treatment of hyperuricemia, and asymptomatic hyperuricemia patients are not recommended. This is because febuxostat inhibits the synthesis of uric acid by inhibiting xanthine oxidase and blocks the source of serum uric acid from the source, so it has a powerful effect of reducing uric acid. However, for asymptomatic patients with hyperuricemia, the increase of uric acid level is closely related to metabolic factors such as high purine diet intake, alcoholism and obesity. It is a lifestyle disease that needs to be controlled through strict and self-disciplined healthy lifestyle adjustment. Although taking drugs can reduce uric acid level in a short time, the safety of taking uric acid-lowering drugs for a long time needs to weigh the benefits and risks. In addition, although the increase of uric acid level will increase the risk of cardiovascular disease, there is no clinical evidence to prove whether lowering uric acid level will reduce the risk of cardiovascular disease. For patients, the concern and compliance of taking uric acid-lowering drugs for a long time is also a problem that needs to be considered in clinic. Because of this, the latest American gout guidelines do not recommend drug treatment for asymptomatic hyperuricemia patients, while the Asian guidelines hold a positive attitude, arguing that active uric acid treatment for asymptomatic hyperuricemia patients can have more clinical benefits, especially cardiovascular benefits, because hyperuricemia will not only induce gout, but also increase the risk of diseases such as diabetes and coronary heart disease. For gout patients, because urate crystals have formed and caused different degrees of damage to joints and kidneys, uric acid reduction therapy has a more positive significance for reducing the number of acute attacks of gout and avoiding further damage of gout to joints, kidneys and cardiovascular system, and the advantages outweigh the disadvantages. In the treatment scheme of reducing uric acid in asymptomatic hyperuricemia, the first-line drugs recommended by China guidelines are benzbromarone and allopurinol, and febuxostat is not recommended, and more consideration is given to febuxostat.
2 Adverse reactions of febuxostat?
Can febuxostat be taken for a long time?